Business Context and Reporting Period
This Form 8-K is a current report filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on August 7, 2007, with the event date of August 13, 2007. The filing discloses the completion of a private placement of equity securities and the entry into material definitive agreements related to the transaction.
Key Financial Metrics
The filing details a capital raise event rather than operational financial performance. Key metrics include:
- Net Proceeds: Approximately $10 million.
- Shares Issued: 1,250,000 shares of common stock.
- Offering Price: $8.00 per share.
- Warrants Issued: 412,500 warrants to purchase additional shares.
- Warrant Exercise Price: $9.50 per share.
- Warrant Terms: Exercisable 181 days after August 13, 2007, with a five-year term.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in equity capital and the potential dilution from the issuance of new shares and warrants. The company entered into a Securities Purchase Agreement and a Registration Rights Agreement, agreeing to register the newly issued stock and underlying warrant shares for resale.
Guidance, Outlook, and Risks
The filing does not contain management guidance, outlook, or specific risk factors beyond standard securities law disclosures. It notes that the securities were issued pursuant to an exemption under Section 4(2) of the Securities Act of 1933 and have not been registered. Consequently, they may not be offered or sold in the United States unless registered or another exemption applies.
Investor Verification Checklist
- Verify the actual closing date of the private placement (August 13, 2007) versus the filing date (August 7, 2007).
- Confirm the total number of outstanding shares post-issuance to assess dilution impact.
- Review the Registration Rights Agreement (Exhibit 10.2) for specific timelines regarding the resale registration.
- Check the press release (Exhibit 99.1) for intended use of the $10 million in proceeds.
- Monitor the warrant exercise window starting 181 days after August 13, 2007.